A Conversation with Dan Renick in Pharmaceutical Commerce
Precision for Value president Dan Renick is interviewed for Pharmaceutical Commerce, providing his in-depth perspective on today’s payer and provider markets.
Commentary: The Challenges of Harmonizing Biomarker Data: Why Trial Success Depends on It
Precision for Medicine’s Scott Marshall and Jared Kohler address the challenges and importance of harmonizing biomarker data in a new editorial for Genetic Engineering and Biotechnology News (GEN). Scott and Jared make the point that generating, tracking, and harmonizing biomarker data and clinical data in real time to inform timely decision-making is critical in modern clinical trials.
Download the New Oncology Research Brief from Precision Health Economics
As healthcare spending continues to rise, payers and providers struggle to accurately measure value to patients, and with health systems all over the world shifting towards paying for value, not just volume, these efforts have never been more important.
Jeremy Schafer Addresses Sanofi/Regeneron’s dupilumab in BioPharm Insight
Precision for Value’s Jeremy Schafer comments on pricing and reimbursement of dupilumab, Sanofi/Regeneron’s first atopic dermatitis biologic, in BioPharm Insight.
Precision for Value’s Hepatitis C Survey Discussed in Managed Healthcare Executive: Here’s What’s Missing
Precision for Value’s Jeremy Schafer highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.